Immunovant, Inc.
corporate_fare Company Profile
Immunovant, Inc. (NASDAQ:IMVT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 14 items for IMVT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 14 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for IMVT spans 10-Q, 8-K, 10-K.
Recent high-impact activity:
- Immunovant Q2 Loss Narrows to $97.2M; $722.3M Cash Funds GD Launch
- Immunovant's IMVT-1402 Hits ACR20 Endpoint in D2T RA; Sjogren's Program Shelved
- Immunovant Posts Narrower-Than-Expected Q2 Loss of $97.2M
- Immunovant's IMVT-1402 Hits Primary Endpoint in D2T RA With 92.5% ACR20 Response
- Immunovant's IMVT-1402 Fails Primary Endpoint in Lupus Study, Development Halted
Financial Snapshot
Short Interest & Short Volume
15.26 days to coverFINRA reported short interest of 18,550,107 shares in IMVT as of the October 30, 2026 settlement, a 1.5% increase from the prior period — about 15.3 days to cover at its recent average daily volume. On November 19, 2026, 61.8% of IMVT volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for IMVT, detected from its recent SEC filings · based on capital-structure filings through 2026-11-09.
New $150M ATM Program Registered · Dilution If Fully Used
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →